ArticleScientific reports2026
Feasibility and utility of a tablet-based digital neurocognitive assessment following radiosurgery for brain metastases.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05504681 (Integration of Neurocognitive Biomarkers Into a Neuro-Oncology Clinic), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Integration of Neurocognitive Biomarkers Into a Neuro-Oncology Clinic
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurocognitive decline (NCD) is a significant concern for patients with brain metastases, yet traditional paper-based assessments are often burdensome. This prospective cohort study evaluated the feasibility and outcomes of a tablet-based digital neurocognitive battery in patients with prior stereotactic radiosurgery (SRS). Data were analyzed from an institutional prospective registry (NCT05504681) including 41 adults with prior SRS. Patients were stratified into a high-risk group (undergoing repeat SRS for progression) and a low-risk group (surveillance only). Neurocognitive function was assessed using the “Cognition” tablet-based platform. NCD was defined as significant deterioration in at least 1 test at 3 months using the Reliable Change Index. The median age was 66 years, and 46% of assessments were conducted in Spanish. Learning and memory were the most frequently affected domains (32%). At 3 months, NCD rates were significantly higher in the high-risk cohort (76%) compared to the low-risk cohort (40%; p = 0.019). On multivariable analysis, risk group status was the only independent predictor of NCD (p = 0.030). Patient feedback indicated high satisfaction and usability. Digital neurocognitive assessment is a feasible and sensitive tool for monitoring patients with brain metastases. The platform effectively differentiated between patients undergoing repeat SRS and those under surveillance, underscoring the importance of routine cognitive monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.